2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatients
2020
A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
Mato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.Peer-Reviewed Original ResearchB-cell lymphomaChronic lymphocytic leukemiaLarge B-cell lymphomaR DLBCLStem cell transplantDuration of responseRichter transformationCombination therapyPrior therapyUnmet medical needTriple combinationPrimary endpointOverall survivalF. Hoffmann-La RocheMedian age 71 yearsMedical needTyrosine kinase inhibitor monotherapyDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaIndolent B-cell lymphomaAdvisory CommitteeMajor unmet medical needDiffuse large B-cell lymphomaHoffmann-La RochePhase ICost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply